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Abstract
Importance
Nalmefene is a newly approved drug for alcohol use disorder, but the risk of harms has not
been evaluated from empirical trial evidence.
Objective
To assess the harm of nalmefene administered to individuals diagnosed with substance use
or impulse control disorders by performing a systematic review and meta-analysis of rando-
mised controlled trials.
Data sources
A search was performed in Cochrane Central Register of Controlled Trials (CENTRAL,
2014), MEDLINE via PubMed (1950), EMBASE via Ovid (1974), and Clinicaltrials.gov
through December 2014.
Study selection
This study included only randomised controlled trials with placebo or active controls that
administered nalmefene to adult individuals for treating impulse control and/or substance
use disorders. Both published and unpublished randomised controlled trials were eligible for
inclusion.
Data extraction and synthesis
Internal validity was assessed using the Cochrane risk-of-bias tool. Published information
from the trials was supplemented by contact between reviewers and industry sponsor. Data
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Data Availability Statement: Data are from 8
different studies; Karhuvaara S, Simojoki K, Virta A,
Rosberg M, Loyttyniemi E, Nurminen T, et al.
Targeted nalmefene with simple medical
management in the treatment of heavy drinkers: a
randomised double-blind placebo-controlled
multicenter study. Alcohol Clin Exp Res 2007
Jul;31(7):1179-87. Grant JE, Potenza MN,
Hollander E, Cunningham-Williams R, Nurminen T,
Smits G, et al. Multicenter investigation of the
opioid antagonist nalmefene in the treatment of
were combined using two meta-approaches in fixed effects models; Peto Odds Ratios and
risk differences were reported with 95% confidence intervals (95%CIs).
Main outcomes and measures
Number of patients with serious adverse events, including specific psychiatric serious
adverse events and withdrawals due to adverse events.
Results
Of 20 potentially relevant studies, 15 randomised controlled trials met the inclusion criteria,
and 8 of these provided data enabling the meta-analysis. Overall, serious adverse events did
not occur more often in the nalmefene group than in the placebo group (Peto Odds Ratio =
0.97 [95% CI 0.64–1.44]; P = 0.86). Risk of psychiatric serious adverse events was slightly
elevated, albeit not at a statistically significant level (Peto Odds Ratio = 1.32 [95% CI 0.62,
2.83]; P = 0.47). Withdrawals due to adverse events were significantly more likely to occur
with nalmefene compared to placebo (Peto Odds Ratio = 3.22 [95% CI 2.46–4.22]; P<0.001)
Conclusions and relevance
The three-fold increased risk of withdrawal from treatment on nalmefene due to adverse
events is a matter of safety concern. The nature of these adverse events cannot be eluci-
dated further without access to individual patients data.
Introduction
Impulse control and substance use disorders are diagnostically separate mental illnesses that,
however, share similar features of pathological behaviours [1]. Impulse control disorder
(which include kleptomania, pathological gambling, pyromania, and intermittent explosive
disorder) are “behavioural addictions” characterized by behaviours and urges that are harmful
to oneself and impair social and occupational function as well as incur legal and financial diffi-
culties [2,3]. Substance use disorder is an addiction characterized by a craving or a strong
desire or urge to use a substance (e.g., drug, alcohol, or nicotine), which leads to clinically sig-
nificant impairment or distress [4]. DSM-5 regards impulse control and substance use prob-
lems as disorders [4], and pharmacological intervention (e.g., with opioid antagonists) is one
of the suggested opportunities for treatment [4].
Because adverse reactions from prescription drugs are so frequent, leading to 4.7% hospital
admissions in the US, pharmacological treatment of impulse control and substance use disor-
ders may lead one to infer adverse or serious adverse events (SAEs). An adverse event is con-
sidered serious by the investigator and sponsor of the trial if any of the following outcomes
occur: death, a life-threatening adverse event, inpatient hospitalization or prolongation of
existing hospitalization, a persistent or significant incapacity or substantial disruption of the
ability to conduct normal life functions, or a congenital anomaly/birth defect [5]. In 1998, 2.7
million hospitalized Americans experienced SAEs from prescription drugs [6]. Furthermore,
mortality from adverse drug reactions is 0.32%, constituting the fourth leading cause of death
in US hospitals [7,8]. Nalmefene hydrochloride dehydrate (nalmefene) is an opioid antagonist
and was approved by the European Medicines Agency (EMA) in 2012 to reduce alcohol con-
sumption in patients with alcohol dependence. To date, no systematic review and meta-
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analysis has been performed regarding harm (SAEs psychiatric SAE or withdrawal due to
adverse events (WD d/t AE) associated with use of nalmefene for substance use and impulse
control disorders. Most of the systematic reviews investigate the effect of treating alcohol
dependence with different drugs [9–16] without addressing the potential harm (e.g., SAEs and
WD d/t AE). According to the EMA’s nalmefene assessment report, oral nalmefene 18 mg/day
is a well-tolerated and efficacious dose and overall, there were no SAEs causing major safety
concern [17]. The report emphasizes that individuals with depressive or psychotic comorbidi-
ties were excluded from the different clinical trials investigating nalmefene; estimates of the
potential psychiatric SAEs of the drug, therefore, are likely conservative [17–20].
In light of the likely increase in drug prescriptions and after approval of nalmefene by EMA
(currently no marketing authorization request to the US Food and Drug Administration), we
performed a systematic review and meta-analysis of RCTs comparing nalmefene with placebo
or active controls to assess nalmefene’s potential for causing harms.
Methods
The definition of harm is “the totality of possible adverse consequences of an intervention or
therapy; they are the direct opposite of benefits, against which they must be compared”[5].
Harms in the present study refer to SAEs, psychiatric SAEs or WD d/t AE.
An event refers to the overall number of SAE, psychiatric SAE or WD d/t AE, in the studies
and is thus not necessarily an expression of any pathological causality between nalmefene and
a specific effect.
The systematic review and the meta-analysis were performed according to the ‘Preferred
Reporting Items for Systematic reviews and Meta-Analyses’ (PRISMA) guidelines for reporting
systematic reviews and meta-analyses [21]. The protocol is registered and available on PROS-
PERO (CRD42014015279).
Selection criteria and search strategy
This study included RCTs with placebo or active controls that administered nalmefene to indi-
viduals for treating impulse control and/or substance use disorders. We sought all placebo-
and active-controls RCTs of nalmefene at any dose for any duration in humans. Both pub-
lished and unpublished RCTs were eligible for inclusion in the systematic review. If the RCTs
had data on harms, the RCTs were eligible for inclusion in the meta-analysis.
Online clinical registries and four bibliographic databases—Cochrane Central Register of
Controlled Trials (CENTRAL, (2014); MEDLINE via PubMed (1950); EMBASE via Ovid
(1974); and Clinicaltrials.gov—were searched through December 2014 for RCTs investigating
the effect and safety of nalmefene compared to any control group. The search strategy is avail-
able from the protocol S1 File.
Online documents available from EMA regarding nalmefene were identified and scruti-
nized for data not available in scientific publications. All RCTs relating nalmefene to substance
use or impulse control disorders were identified. Furthermore, the reference lists of all appar-
ently relevant review articles and included studies were manually searched to identify other
potentially relevant RCTs. One reviewer (KGVJ) screened all references by titles and abstracts
according to the eligibility criteria. Full text papers were retrieved for further assessment if the
abstract information suggested that the study compared nalmefene with placebo or an active
comparator and included participants with impulse control or substance use disorders. Two
reviewers (KGVJ, ST) assessed full-text papers for the systematic review.
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Data collection, data items, and risk-of-bias assessment
Data were extracted by one reviewer (KGVJ) and confirmed by a second reviewer (ST). Pri-
mary outcome measures were extracted as the overall number of nonspecific SAEs, defined by
the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use events [5], both in the nalmefene and in the control
groups. Secondary outcomes are specific SAEs (e.g. all cause mortality) and specific psychiatric
SAEs emphasizing depression, anxiety, suicidal attempts, suicidal ideation, and suicide. Fur-
thermore, data were extracted on WD d/t AE. For exploratory qualitative purposes, all types of
SAEs reported in the different trials were also extracted. We included all the aforementioned
outcomes regardless of whether or not we believed that SAEs, psychiatric SAEs or WD d/t AE
were related or not to drug treatment.
The Cochrane risk-of-bias tool was used to assess whether there was high, low, or unclear
risk of bias in the following domains: sequence generation, allocation concealment, blinding,
incomplete outcome data, and selective outcome reporting [22]. KGVJ and ST assessed the
risk of bias independently for all included studies. Discrepancies were resolved by referring to
the original publications and discussing with a third reviewer (RC). Study characteristics based
on condition, trial duration, and number of participants (including doses and the percentage
of males participating) were abstracted from the eligible trials.
Statistical analyses
We described study characteristics according to sample size and characteristics of study partic-
ipants, including mental illness condition (e.g. substance use disorder or impulse control dis-
order) and trial duration. Review Manager (5.3) was used to conduct all the meta-analyses.
Because our outcomes of interest are rare, we followed recommendations of Bradburn and col-
leagues [23] and used Peto odds ratios (PORs) under fixed effects models to compare nalme-
fene and placebo/active comparator groups. We also undertook meta-analyses using Mantel-
Haenszel risk differences (RD) under fixed effects models. We present results using both a rel-
ative measure as PORs and an absolute measure as RD. We reported results using 95% confi-
dence intervals (95%CIs) and forest plots for both measures so that findings can be compared.
Statistical heterogeneity was assessed with the I-squared statistic [24]; we assigned adjectives of
low, moderate, and high to I2 values of 25%, 50%, and 75%, respectively [25]. A relevant study-
level covariate was defined a priori as one that was able to decrease the between-study variance
(tau-squared, and thus the I-squared statistic)[24]. Risk of bias across RCTs was assessed by
using stratified analyses for each of the domains included in the risk-of-bias tool [22].
Patient involvement
No patients were involved in setting the research question or the outcome measures, nor were
they involved in the design and implementation of the study and there are no plans to involve
the patients in the dissemination of the results.
Results
The bibliographic searches identified 795 references, and after removal of 323 duplicates across
the different data sources, 472 titles and abstracts were screened (Fig 1). From these, 441 rec-
ords were excluded based on abstract and title (93%). Of the remaining 31 records S2 File, a
further 11 full-text articles were excluded based on the eligibility criteria. Thus, 20 records
were identified as potentially eligible RCTs retrieved for further scrutiny S2 File. Two of the 20
records [26,26,27] were spinoff papers of two already included RCTs [19,28]. One record that
Harms associated with taking nalmefene
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was simply excluded from the study since the record wasn’t an RCT [29,29], and two other
RCTs were pooled analyses of included RCTs [30,31].
Ultimately, eight studies were used as the basis of the statistics on harms from nalmefene
[19,20,32–37]. 15 fulfilled eligibility requirements [18–20,28,32–38,38–41] but were further
whittled down to 8 because of missing data on harms.
Table 1 illustrates the study characteristics and the risk-of-bias assessment of the 15 RCTs
included in the systematic review. From these 15 RCTs, two were ongoing studies [39,41].
The remaining 13 completed RCTs, undertaken between 1994 and 2014, were multicenter
studies, with a total of 3,793 participants (based on the intention-to-treat populations)
assessed. The mean age for participants in the included studies ranged from 30.3 to 51.6 years.
In the included studies, most of the participants were male; the majority ranged from 58 to
81%. Trial durations varied from one day to 52 weeks, and the participants received either
5–100 mg/day nalmefene or 25–50 mg/day of naltrexone, or placebo. Of the 15 completed
RCTs, five did not report on SAEs or WD d/t AE [17,18,28,38,38,40]. Eight RCTs were
included in the meta-analysis [19,20,32–37]. All eight RCTs reported WD d/t AE. Six RCTs,
reported both on SAEs and WD d/t AE [19,32–34,36,37]. Two of these eight RCTs did not
report on SAEs, and data could not be identified through other sources; hence we deemed
these two RCTs [20,35] a high risk of selective-outcome-reporting bias. Three of the eight
RCTs used as-treated data instead of intention-to-treat data and therefore were considered
high risk of incomplete-data bias [32,36,37].
Fig 1. Flow chart showing selection of randomized controlled trials for inclusion in systematic review
of nalmefene.
https://doi.org/10.1371/journal.pone.0183821.g001
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Table 1. Study characteristics including the risk of bias assessment of randomised controlled trials of nalmefene included in the systematic
review.
Author, Year, (Ref) Outcomes
Included
Condition Trial
duration
No. of
patients
Male Mean
age
Risk of
bias
Opioid
antagonist
Daily
dose
No. of
patients
Included in the meta-
analysis*
in meta-
analysis
(Weeks) randomised (%) year Δ (mg)
Anton et al 2004 WD d/t AE Alcohol Use
Disorder
12 270 210 45.0 U/U/U/
U/I
Nalmefene 40 68
CPH-101-0299 (78) Nalmefene 20 66
[35](*) Nalmefene 5 68
Placebo 0 68
Grant et al 2006 WD d/t AE Gambling
Disorder
16 207 116 45.9 A/U/U/
U/I
Nalmefene 100 52
[20](*) (56) Nalmefene 50 52
Nalmefene 25 52
Placebo 0 51
Gual et al 2013 SAE Alcohol Use
Disorder
24 718 503 44.8 A/A/A/I/
A
Nalmefene 18 358
NCT 00812461 Anxiety (70) Placebo 0 360
(ESENSE 2) Depression
[37](*) WD d/t AE
Karhuvaara et al 2007 SAE Alcohol Use
Disorder
28 403 326 49.2 A/A/A/
A/U
Nalmefene 10–40 242
CPH-101-0801 WD d/t AE (81) Placebo 0 161
[19](*)
Mann et al 2013 SAE Alcohol Use
Disorder
24 604 405 51.6 A/A/A/I/
A
Nalmefene 18 306
NCT00811720 Anxiety (67) Placebo 0 298
(ESENSE 1 Depression
[36](*) WD d/t AE
Mason et al.1994 SAE Alcohol Use
Disorder
12 21 15 42.0 U/A/U/
U/A
Nalmefene 40 7
[34](*) WD d/t AE (71) Nalmefene 10 7
Placebo 0 7
Mason et al 1999 SAE Alcohol Use
Disorder
12 105 70 41.8 U/A/U/
A/A
Nalmefene 20–80 70
[33](*) WD d/t AE (67) Placebo 0 35
Van den brink et al
2014
SAE Alcohol Use
Disorder
52 675 506 44.3 A/A/A/I/
A
Nalmefene 18 499
(SENSE) Anxiety (75) Placebo 0 163
NCT00811941 Depression
[32](*) WD d/t AE
Grant et al 2010 NA Gambling
Disorder
10 233 135 46.5 A/U/U/
U/I
Nalmefene 40 82
[18] (58) Nalmefene 20 77
Placebo 0 74
Drobes et al.2000 NA Alcohol Use
Disorder
1 25 20 35.1 U/U/U/
U/I
Naltrexone NA NA
[40] (80) Nalmefene NA NA
Placebo 0 NA
(Continued )
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The objectives of the available studies in the meta-analysis were to examine the safety and
efficacy of nalmefene for reducing alcohol consumption in alcohol-dependent patients [33–
37], to evaluate the long-term efficacy and safety of nalmefene in reducing alcohol consump-
tion [32], to determine the effect and safety of nalmefene in reducing heavy drinking [19], and
to examine the efficacy and tolerability/safety of nalmefene in reducing of pathological gam-
bling [20].
Harms observed
Six of the ultimately eight RCTs that were used as the basis of the statistics on harms from nal-
mefene reported SAEs (Fig 2). Forest plot of odds (Peto odds ratio) and risk (Mantel-Haenszel
risk difference) of serious adverse event associated with nalmefene use compared to placebo.
Every square represents the individual study’s serious adverse events estimates with 95% CI
indicated by horizontal line. We found no evidence of increased odds of SAEs in the nalme-
fene group compared with the placebo group. The Peto Odds (POR) for nalmefene versus pla-
cebo was POR 0.97 (95% CI 0.64 to 1.44; P = 0.86; I2 = 18%), and the Risk difference (RD) was
-0.00 (-0.02 to 0.01; P = 0.84; I2 = 0%). There was no reason to suspect a rejection of the
hypothesis of homogeneity based on the P value in the POR method Q = 3.65; P = 0.30.
Table 1. (Continued)
Author, Year, (Ref) Outcomes
Included
Condition Trial
duration
No. of
patients
Male Mean
age
Risk of
bias
Opioid
antagonist
Daily
dose
No. of
patients
Included in the meta-
analysis*
in meta-
analysis
(Weeks) randomised (%) year Δ (mg)
Drobes et al.2003 NA Group a) 1 125 NA 30.3 A/U/U/
U/I
Naltrexone 25–50 39
[28] Alcohol Use
Disorder
Nalmefene 20–40 36
Placebo 0 50
Group b) 1 90 NA 32.0 A/U/U/
U/I
Nalmefene 25–50 29
social drinkers Nalmefene 20–40 31
Placebo 0 30
Somaxon
pharmaceuticals
NA/on Smoking Use
Disorder
5 NA NA NA NA Nalmefene 80 NA
[39] Nalmefene 40 NA
Placebo 0 NA
Lundbeck A/S 2014 NA/on Alcohol Use
Disorder
1+1day 100 NA NA NA Nalmefene 18 NA
[41] Placebo 0 NA
Biotie NA Alcohol Use
Disorder
28 167 NA NA NA Nalmefene 40 82/3
CPH-101-0701 Nalmefene 20 NA
[38] Nalmefene 10 NA
Placebo NA 85
Biotie NA Alcohol Use
Disorder
16 150 NA NA NA Nalmefene 40 50
CPH-101-0399 Nalmefene 10 50
[38] Placebo 0 50
ΔRisk of bias: sequence generation/concealment of allocation/blinding of participants and investigators/incomplete outcome data/selective outcome data.
A = Adequate (low risk of bias); U = Unclear (unclear risk of bias); I = Inadequate (high risk of bias). NA = data not available. DSM-5 = Diagnostic and
Statistical Manual of Mental Disorders. SAE = serious adverse event. WD d/t AE = withdrawal due to adverse event.
* Included in the meta-analysis.
https://doi.org/10.1371/journal.pone.0183821.t001
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Three out of the six RCTs that reported SAEs categorized SAEs into different sub-disorders
such as psychiatric disorders or death. To analyse secondary harm outcomes, we used the over-
all number of psychiatric SAEs S1 Fig; the POR for nalmefene versus placebo was POR 1.32
(95% CI 0.62 to 2.83; P = 0.47, I2 = 40%). The RD was 0.00 (-0.01 to 0.01; P = 0.40, I2 = 72%).
In other words, we found no evidence of increased odds of overall psychiatric SAEs in the nal-
mefene group compared with the placebo group. Based on the Cochrane Q statistic test, homo-
geneity among the studies was present according to the p-value in the POR method Q = 3.33,
P = 0.19. However, the analysis showed a moderate degree of inconsistency among the study
findings according to their I2 values.
After we have analysed the overall number of psychiatric SAEs we subcategorized psychiat-
ric SAEs into depression, anxiety, and mortality (including completed suicide and sudden
death). Of the six studies mentioned above, three reported depression; the POR was 5.48 (95%
CI 0.28 to 106.79; P = 0.26, I2 = 0%). The RD was 0.00 (-0.01 to 0.01; P = 0.60, I2 = 0%). For
anxiety; the POR was 3.77 (95% CI 0.04 to 355.81; P = 0.57, I2 = Not applicable. Hence, only
one study reported events on anxiety). The RD was 0.00 (-0.00 to 0.00; P = 0.87, I2 = 0%). Mor-
tality, including suicide and sudden death, was reported in three RCTs (total 1/1144) in the
nalmefene group and 2/797 in the placebo group). The POR for mortality was 0.50 (95% CI
0.05 to 4.85; p = 0.55, I2; = 63%) and the RD was -0.00 (-0.01 to 0.01; P = 0.93, I2 = 0%). Based
on the Cochrane Q statistic test, homogeneity among the studies was present Q = 2.68;
P = 0.10. We found no evidence of an increased risk of depression, anxiety, or death in the nal-
mefene group compared with the placebo group. A list of all different reported SAEs in the
included studies is presented in S1 Table.
Eight RCTs in the meta-analysis reported WD d/t AE (Fig 3). Forest plot of odds (Peto
odds ratio) and risk (Mantel-Haenszel risk difference) of withdrawals due to adverse events
associated with nalmefene use compared to placebo. Every square represents the individual
study’s withdrawals due to adverse events estimates with 95% CI indicated by horizontal line;
the POR was 3.22 (95% CI 2.46 to 4.22; P<0.00 I2; = 0%). The RD was 0.09 (0.08 to 0.11;
P = 0.00, I2 = 86%). Based on the Cochrane Q statistic test, homogeneity among the studies
was present according to the p-value in the POR method Q = 3.69; P = 0.81.
Fig 2. Serious adverse events of nalmefene compared to placebo in patients with substance use or/and
impulse control disorder.
https://doi.org/10.1371/journal.pone.0183821.g002
Fig 3. Withdrawals due to adverse events of nalmefene compared to placebo in patients with substance
use or/and impulse control.
https://doi.org/10.1371/journal.pone.0183821.g003
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Additional analyses
The risk of bias across RCTs according to the major outcome (SAE) was assessed by using sub-
group analyses for each of the five domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, and selective outcome reporting stated in the Cochrane
risk-of-bias tool, including if the RCTs were using the as-treated or intention-to-treat principle
S2 Table. The subgroups’ differences for sequence generation, allocation concealment, and
blinding were not applicable because all the included studies provide data only in the adequate
categorizations in the above mention domains. For Intention to treat (P = 0.57), incomplete
outcome data (P = 0.57), and selective outcome reporting (P = 0.57), the differences among
the groups were not significant.
Even if there are similarities as indicated in the diagnostics, the abuse of alcohol can very
well have changed or modulated biology so that response to a drug and also potential WD t/t
AE. Since the risk of WD d/t AE was more than 3 times likely for the patient in the nalmefene
group than for the placebo group, a subgroup analysis stratified in two groups, substance use
disorder and impulse control disorder was made S2 Fig. The subgroup differences for the two
groups were P = 0.57; I2 = 0%, the differences between the two groups were not significant.
Discussion
This meta-analysis of eight RCTs involving 1,828 patients with substance use or impulse con-
trol disorder who were prescribed nalmefene and 1,119 patients who were prescribed placebo
found no increased risk of SAEs compared to placebo. However, patients taking nalmefene
were 3.22 times more likely to discontinue therapy due to side effects compared to placebo. In
the WD d/t AE stratified analysis, no statistical differences among the two groups were
observed.
Treatment with nalmefene did not increase risk of death when compared to placebo. The
overall psychiatric SAEs apparently occurred more frequently, but not statistically significantly
in the nalmefene group compared to placebo. In the risk-of-bias stratified analyses, no statisti-
cal differences among the different groups in the risk-of-bias tool were observed.
Comparison with other studies
Currently there is no systematic review and meta-analysis report on SAEs associated with use
of nalmefene for substance use or impulse control disorders. Two meta-analyses by Jones et al.
and Ro¨sner et al. reported on the effect of different pharmaceutical treatments for alcohol
dependence and included an analysis of WD d/t AE [10,15]. Jonas et al. included 135 studies,
seven of which compared nalmefene with placebo [10,11]. Compared with placebo, partici-
pants treated with nalmefene or naltrexone had a higher risk of WD d/t AE. In one study two
participants in placebo group committed suicide. In another trial one patient allocated to the
placebo group died of hepatocellular carcinoma and one patient randomised to nalmefene
died suddenly for unknown causes. In studies comparing nalmefene with placebo, four cases
of suicide attempts or suicidal ideation in nalmefene group and 9 in placebo group were
reported. Ro¨sner et al. included 50 RCTs, including three studies comparing nalmefene to pla-
cebo (13). Compared to the placebo group, patients in the nalmefene group had a 43% higher
risk of WD d/t AE. The dropout rates were not statistically significant [15]. SAEs were not
reported as an outcome or calculated in that meta-analysis. Our meta-analysis has shown a
similar trend according to withdrawals due to adverse events in the nalmefene group com-
pared to placebo group.
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Strengths and limitations
To the best of our knowledge, ours is the most comprehensive systematic review and meta-
analysis of harm associated with using nalmefene to treat impulse control and substance use
disorders.
Our systematic review was rigorously performed and reported according to the PRISMA
statement [21]. A highly sensitive search strategy was used in order to identify as many rele-
vant studies as possible and to reduce potential publication bias. An extensive range of
resources was searched, including electronic databases, guidelines, and references listed in
other systematic reviews. Both published and unpublished RCTs were eligible for inclusion in
the systematic review and if the RCTs had data on harms, the RCTs were eligible for inclusion
in the meta-analysis. We present results using both a relative measure as Peto Odds Ratio and
an absolute measure as Risk Difference with a fixed effect model. We used the Cochrane risk-
of-bias tool to assess the internal validity in all the included studies.
Our results were limited by a lack of access to all available sources reporting safety data,
including unpublished RCTs and RCTs in progress, as well an absence in several trials of con-
sistent reporting of psychiatric SAEs. Additionally, the secondary endpoints reported in the
studies were depression, anxiety, suicidal attempts, suicidal ideation, and suicide and mortal-
ity; some of these phenomena had very different severity and clinical implications. In all the
studies, the enrolled patient populations were highly selected, as patients with a history of
comorbid psychiatric disorder were excluded from the studies. For these reasons, our esti-
mates of psychiatric SAEs are probably conservative, and our results cannot be extended to
populations of patients with substance use or impulse control disorders and other psychiatric
comorbidity.
Many of the RCTs included in the meta-analysis were relatively small and short-term,
resulting in few events; our study, therefore, was not able to effectively discuss the risk for fur-
ther SAEs in larger studies. The limited number of events resulted in PORs that could be
affected by small changes in the classification of events and may have caused problems con-
cerning heterogeneity in the meta-analysis. The confidence intervals for the PORs for SAEs,
WD d/t AE, and deaths were wide, resulting in considerable uncertainty about the magnitude
of the observed odds.
We did not have full access to all original source data, and we based the meta-analysis on
available data from publications. However, we found two RCTs in the Selincro assessment
report [17] and in the Biotie Therapies Corp. update [38]. These RCTs had not yet been pub-
lished; hence, we weren’t able to include them in the meta-analysis together with the risk-of-
bias analysis. Two RCTs had not been completed—one for using nalmefene for smoking cessa-
tion and one for using nalmefene to treat alcohol dependence [39,41]. Ongoing RCTs may
provide useful data, which could have increased the probability for significance within our pri-
mary and/or secondary results had it been possible to include them [39,41].
According to our objective, the two domains—selective outcome reporting and incomplete
outcome data—were both considered as important domains in the risk-of-bias tool. Based on
these tools, five RCTs had high risk of bias from selective outcome reporting and an unclear
risk of bias from incomplete outcome data. Another three RCTs had a high risk of bias from
incomplete outcome data, resulting in as-treated data’s being used. The proportion of informa-
tion from RCTs at high risk of bias in the key domains was sufficient to affect the interpreta-
tion and validity of the result. Some of the results were not applicable because some outcomes
were not estimable in some of the groups, which decreased the reliability of our study’s results.
The manufacturers’ and authors’ public disclosure of safety results for nalmefene RCTs
were not sufficient to enable a robust assessment of specifically the risk of SAEs from
Harms associated with taking nalmefene
PLOS ONE | https://doi.org/10.1371/journal.pone.0183821 August 29, 2017 10 / 14
nalmefene. The manufacturers and authors have available all source data for completed RCTs
and should make these data available due to ethical considerations. If more manufacturers and
authors chose to strictly follow good clinical practice (GCP), harmonization of technical
requirements for registration of pharmaceuticals for Human Use (ICH) and the CONSORT
Statement for better reporting of harm in randomised trials [5], then market transparency will
increase, resulting in greater chances for improved validity.
Conclusions and clinical implications
Based on our systematic review of published RCTs, there is no evidence of an increased risk of
SAEs including psychiatric SAEs and death from any cause associated with treatment with nal-
mefene for substance use and impulse control disorders. Nalmefene users, however, have an
increased risk of WD d/t AE, which are consistent with findings from other systematic reviews.
However, this conclusion is based upon a highly selected group of patients; a more representa-
tive selection procedure may not rule out the possibility of more adverse events. This risk
seems to be supported by an “increased risk of WD d/t AE," which likely reflects the ultimate
decision of the participant and physician to quit the intervention due to side effects.
The findings of our meta-analysis suggest a risk of WD d/t AE associated with use of nalme-
fene compared to placebo, but the risk of SAEs remains unclear until more precise estimates of
SAEs associated with nalmefene treatment in patients suffering from substance use or impulse
control disorder has become available. Further studies are needed to enable a more robust
assessment of the harm of nalmefene. Large RCTs with more participants in both groups and a
balance in the number of participants in the groups, comparing placebo with nalmefene,
reporting on both SAEs and WD d/t AE, with use of Intention-to-treat data are strongly rec-
ommended to strengthen the evidence base for treatment with nalmefene.
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